Unlock instant, AI-driven research and patent intelligence for your innovation.

Oncolytic measles virus

A measles virus and oncolytic technology, which is applied in the field of preparing the recombinant measles virus required in this article, can solve the problems of increasing cost and complicating recombinant measles virus particles, and achieve the effect of reducing cost

Inactive Publication Date: 2013-07-10
乌尔里希·M·劳尔 +7
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Furthermore, measles virus preparations are generally never rescued from cell lines approved for vaccine production like chicken embryo fibroblast (CEF) cells or 293 human embryonic kidney cells, both of which complicate large-scale production of GMP-compliant recombinant measles virus particles and thus increase the cost

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oncolytic measles virus
  • Oncolytic measles virus
  • Oncolytic measles virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Example 1: MeV cDNA plasmid vector pc3MerV2 Preparation of Id-Trka (SEQ-ID NO.3)

[0109] The preparation of the measles virus cDNA vector was performed essentially as recently described (Inoue K, Shoji Y, Kurane I, lijima T, Sakai T, Morimoto K. J Virol Methods. 2003; 107:229-36; Martin A, Staeheli P, Schneider U.J Virol. 2006;80:5708-15), but with the following important modifications.

[0110] - Initially, it was not clear (i) which sequence part / fragment of the widely used cytomegalovirus (CMV) RNA polymerase II (PolII) promoter must be replaced when used to rescue and amplify recombinant measles virus vectors considered optimal and (ii) which of the different CMV viral genomes described in GenBank (M60321, M21295) should be used for the production of CMV-based minimal promoters; therefore, priming of different minimal CMV sources had to be done first Systematic analysis of subconstructs; the results of this study showed a promoter variant construct, pc3, cover...

Embodiment 2

[0134] Embodiment 2: MeV Id-SCD (Id-SCD) plasmid vector pc3MerV2 Preparation of Id-SCD (SEQ-ID NO.4)

[0135] To generate the recombinant MeV Id-SCD (Id-SCD) measles virus vector, the plasmid pUC-SCD encoding the SCD suicide fusion gene was digested with the restriction enzyme Mlu1 and the fragment containing the open reading frame of the SCD suicide fusion gene Ligated into the base vector pc3MerV2 Id-Trka (a derivative of the parental pc3 containing an optimized (shortened and modified) CMV RNA polymerase II (Pol II) promoter) that had been linearized with the restriction enzyme AscI. Correctly integrated fragments were confirmed by restriction digestion and sequencing. Infectious virus particles were successfully produced by subsequent rescue procedures.

[0136] pc3MerV2 Id-SCD (SEQ-ID NO. 4). The sequence of pc3MerV2 Id-SCD (see figure 2 ) can be described with reference to the position of the nucleotide (nt) below:

[0137] -nt 1-55: MeV leader sequence

[01...

Embodiment 3

[0157] Embodiment 3: help the preparation of plasmid (SEQ-ID NO.5 to 7).

[0158] Preparation of helper plasmids carrying N, P or L genes respectively was performed essentially as recently described (Martin A, Staeheli P, Schneider U.J Virol. 2006; 80:5708-15), but with the following important modifications:

[0159] - As a result of a systematic analysis of different minimal CMV-derived promoter constructs, the promoter variant construct pc3 was found to give the best yield both in virus rescue and virus amplification, and was also used to aid in plasmid production;

[0160] - lack of intronic sequence in the minimal pc3 CMV promoter (301nt+3nt) prevents mRNA guidance of the splicing mechanism prior to mRNA export from the nucleus; thus reduced splicing efficiency improves measles virus rescue and amplification;

[0161] - In addition, a Hepatitis Delta Virus (HDV) ribozyme purposefully incorporated at the 3' position was used to precisely process the 3' end of all transcri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising a recombinant measles virus comprising a suicide gene for use in the treatment of malignant cells with primary or secondary resistance to an oncolytic measles virus without suicide gene activity. Furthermore, the present invention relates to a recombinant measles virus comprising a suicide gene comprising yeast cytosine deaminase and A fusion of yeast uracil ribosyltransferase. Background technique [0002] Despite the remarkable advances that have been made in the past in, for example, chemotherapy, antibody-based therapies, tumor vaccines, and radiation therapy, there remains an urgent and unmet need to develop new therapeutic approaches and pathways for tumors and related malignancies . [0003] Although the gene therapy approach is actually promising for these treatments and anti-tumor results have been observed in different gene therapy models, certain limitations especiall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76C12N15/45A61P35/00C12N9/10C12N9/78C07K19/00A61K35/768
CPCA61K31/7088A61K35/768A61P35/00C07K2319/00C12N9/1077C12N9/78C12N2760/18432C12N2830/60C12Y305/04001C12N7/00C12N2760/18421C12N2760/18443C12N2760/18471
Inventor 乌尔里希·M·劳尔米夏埃尔·比策约翰娜·兰珀马尔蒂安·齐默尔曼苏珊·贝希托尔德塞巴斯蒂安·朗格沃尔夫冈·J·诺伊尔特萨沙·博索
Owner 乌尔里希·M·劳尔